| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5900488 | Diabetes Research and Clinical Practice | 2011 | 4 Pages |
Abstract
A randomized, crossover study compared the effects of atorvastatin, gemfibrozil and their combination on inflammatory markers in type 2 diabetes. C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), secretory phospholipase A2 (sPLA2), interleukin 8 (IL8), monocyte chemotactic protein 1 (MCP1) and tumor necrosis factor α (TNFα) were measured. Both lipid-lowering drugs had positive, complementary and additive effects on inflammatory markers, which were closely related to baseline inflammatory status.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Ana MarÃa Wägner, Jose Luis Sánchez-Quesada, Sonia BenÃtez, Cristina Bancells, Jordi Ordóñez-Llanos, Antonio Pérez,